Can Combination MEK and Akt Inhibition Slay the Giant Congenital Nevus?

Brandon M Murphy; Christin E Burd

doi:10.1016/j.jid.2019.04.009

Can Combination MEK and Akt Inhibition Slay the Giant Congenital Nevus?

J Invest Dermatol. 2019 Sep;139(9):1857-1859. doi: 10.1016/j.jid.2019.04.009.

Authors

Brandon M Murphy¹, Christin E Burd²

Affiliations

¹ Department of Cancer Biology and Genetics, Ohio State University, Columbus, Ohio, USA.
² Department of Cancer Biology and Genetics, Ohio State University, Columbus, Ohio, USA; Department of Molecular Genetics, Ohio State University, Columbus, Ohio, USA. Electronic address: [email protected].

Abstract

The clinical management of large and giant congenital melanocytic nevi (lgCMN) relies heavily upon iterative surgical procedures. In this issue Rouille et al. (2019) use lgCMN explants and a newly developed patient-derived xenograft model to show that the local administration of MEK and Akt inhibitors limits the lgCMN proliferative potential. These findings, along with emerging reports, support continued investigation of targeted therapies in lgCMN.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Humans
Nevus, Pigmented*
Proto-Oncogene Proteins c-akt
Skin Neoplasms*

Substances

Proto-Oncogene Proteins c-akt

Abstract

Publication types

MeSH terms

Substances

Grants and funding